Universities of Cologne
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1388-01-01
- Employees
- 251
- Market Cap
- -
Clinical Trials
205
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (143 trials with phase data)• Click on a phase to view related trials
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma (Category)
- Interventions
- Drug: BrECADD
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 35
- Registration Number
- NCT06919679
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 50
- Registration Number
- NCT06916416
A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis
- Conditions
- Extrapulmonary Tuberculosis
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 150
- Registration Number
- NCT06875336
- Locations
- 🇩🇪
University Hospital Bonn, Bonn, Germany
🇩🇪Research Center Borstel, Borstel, Germany
🇩🇪University Hospital of Cologne, Cologne, Germany
Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Syndrome in Patients With Profound Hyponatremia in the Emergency Department
- Conditions
- Hyponatremia
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1000
- Registration Number
- NCT06781710
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
Vaccine-induced Immunity in Immunocompromised Patients
- Conditions
- Immunodeficiency
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 5000
- Registration Number
- NCT06612515
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, NRW, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 40
- Next
News
Cancer Drug Combination Extends Mouse Lifespan by 30% in Aging Research Breakthrough
Researchers demonstrated that combining trametinib and rapamycin, two existing cancer drugs, extends mouse lifespan by approximately 30%, significantly more than either drug alone.
Cefiderocol Shows Higher Efficacy When Used Earlier in Treatment of Serious Gram-Negative Infections
New data from the PROVE study reveals cefiderocol achieves better clinical outcomes when used as empiric (64.6%) or documented therapy (67.4%) compared to salvage therapy (58.2%) in serious gram-negative infections.
MATTERHORN Trial: TEER Non-Inferior to Surgery for Secondary Mitral Regurgitation
The MATTERHORN trial demonstrated that transcatheter edge-to-edge repair (TEER) is non-inferior to surgery in treating secondary mitral regurgitation (MR) at one year.